EP 1425004 A1 20040609 - USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO THE CENTRAL CANNABINOID RECEPTORS
Title (en)
USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO THE CENTRAL CANNABINOID RECEPTORS
Title (de)
VERBINDUNGEN ZUR VERWENDUNG ALS ZENTRALE CANNABINOID-REZEPTOR-ANTAGONISTEN
Title (fr)
UTILISATION DE COMPOSES EN TANT QU'ANTAGONISTES FONCTIONNELS DES RECEPTEURS CANNABINOIDES CENTRAUX
Publication
Application
Priority
- EP 0207722 W 20020711
- IT MI20011483 A 20010711
Abstract (en)
[origin: WO03006007A1] The invention refers to the use of saturated fatty acid acylamide derivatives as functional antagonists to the central cannabinoid receptors. These molecules, per se devoid of the psychotropic effects of classic cannabinoids, aminoalkylindoles, endocannabinoids known today, have the ability to behave as functional antagonists of the central cannabinoid receptors, when administered by different routes. For their pharmacological activity they are therefore suitable as drugs in pathological states or disorder which can be controlled through a reduction in the functionality of said receptors or through a reduction of the effect of the same endocannabinoids also caused by a reduced availability or affinity of the receptors.
IPC 1-7
A61K 31/195; A61P 1/00; A61P 25/30; A61P 37/00; A61P 1/16; A61P 25/00
IPC 8 full level
A61K 31/195 (2006.01); A61P 1/00 (2006.01); A61P 1/16 (2006.01); A61P 25/00 (2006.01); A61P 25/30 (2006.01); A61P 37/00 (2006.01)
CPC (source: EP)
A61K 31/195 (2013.01); A61P 1/00 (2017.12); A61P 1/16 (2017.12); A61P 25/00 (2017.12); A61P 25/30 (2017.12); A61P 37/00 (2017.12)
Citation (search report)
See references of WO 03006007A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
DOCDB simple family (publication)
WO 03006007 A1 20030123; EP 1425004 A1 20040609; IT MI20011483 A0 20010711; IT MI20011483 A1 20030111
DOCDB simple family (application)
EP 0207722 W 20020711; EP 02764671 A 20020711; IT MI20011483 A 20010711